Login to Your Account

Other News To Note

Thursday, January 24, 2013

• Cytos Biotechnology Ltd., of Zurich, Switzerland, said partner Novartis AG, of Basel, Switzerland, will discontinue development of NIC002, a therapeutic vaccine candidate for treating nicotine addiction.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription